<DOC>
	<DOCNO>NCT01600092</DOCNO>
	<brief_summary>A study compare safety , tolerability , immunogenicity new formulation RotaTeq™ exist formulation infant . The primary hypothesis study new formulation noninferior exist formulation basis immunogenicity .</brief_summary>
	<brief_title>A Study Immunogenicity , Tolerability , Safety New Formulation RotaTeq™ Infants ( V260-035 )</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<criteria>Parent legal guardian agree infant participate give write informed consent History congenital abdominal disorder , prior rotavirus gastroenteritis , chronic diarrhea , failure thrive , abdominal surgery History intussusception Known suspect impairment immunological function , include Severe Combined Immunodeficiency ( SCID ) Prior administration rotavirus vaccine Clinical evidence active gastrointestinal illness , exception wellcontrolled gastroesophageal reflux disease ( GERD ) Receipt 1 ) systemic corticosteroid ( ≥ 2mg/kg total daily dose prednisone equivalent ) 14 consecutive day since birth , 2 ) systemic corticosteroid ≥ 2mg/kg/dose within 7 day prior administration first dose study vaccine . Participant use nonsystemic corticosteroid eligible vaccination . Residing household immunocompromised person Prior receipt blood transfusion blood product , include immunoglobulin Participation another interventional study within 14 day prior first study vaccination expect anytime study Receipt investigational inactivate vaccine within 14 day investigational live vaccine within 28 day prior first study vaccination expect anytime study</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>